How much funding has Mnemo Therapeutics raised?

Mnemo Therapeutics has raised $91.0M in total funding, most recently a Series A round.

Who are Mnemo Therapeutics's investors?

Mnemo Therapeutics's investors include Casdin Capital, Sofinnova Partners.

When was Mnemo Therapeutics founded?

Mnemo Therapeutics was founded in 2019.

Where is Mnemo Therapeutics headquartered?

Mnemo Therapeutics is headquartered in Paris, France.

What industry is Mnemo Therapeutics in?

Mnemo Therapeutics operates in Biotech.

How many employees does Mnemo Therapeutics have?

Mnemo Therapeutics has 51-200 employees.

Mnemo Therapeutics

Paris, France · Founded 2019 · $91.0M raised

Biotech

Headquarters: Paris
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: mnemo-tx.com
Total Funding: $91.0M
Last Round: $91.0M Series AJun 2021
Rounds: 1

About

Mnemo Therapeutics is a Paris-based clinical-stage biotechnology company founded in 2019. The company focuses on improving the efficacy of T cell-based cancer immunotherapies — including CAR-T and TCR-T therapies — by applying epigenetic reprogramming techniques to enhance T cell persistence, memory, and anti-tumor activity. Mnemo's platform identifies and modulates the epigenetic regulators that govern T cell fate, aiming to produce immune cells with superior durability in the tumor microenvironment. Headquartered at 101 Boulevard Murat in Paris, the company raised a €75M Series A in 2021 and has conducted research collaborations with the Institut Curie and other academic partners.

Summary

Mnemo Therapeutics is a Biotech company based in Paris, France, founded in 2019. It has raised $91.0M in total across 1 round, most recently a $91.0M Series A round in Jun 2021. Investors include Casdin Capital and Sofinnova Partners.